PDE5 inhibition ameliorates visceral adiposity targeting the miR-22/SIRT1 pathway: Evidence from the CECSID trial

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 4, 2016, Pages 1525-1534

  Fiore, Daniela ^a   Gianfrilli, Daniele ^a   Giannetta, Elisa ^a   Galea, Nicola ^b   Panio, Giuseppe ^a   Di Dato, Carla ^a   Pofi, Riccardo ^a   Pozza, Carlotta ^a   Sbardella, Emilia ^a   Carbone, Iacopo ^b   Naro, Fabio ^a   Lenzi, Andrea ^a   Venneri, Mary A ^a   Isidori, Andrea M ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 22; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; SIRTUIN 1; MICRORNA; MIRN22 MICRORNA, HUMAN; PDE5A PROTEIN, HUMAN; PHOSPHODIESTERASE V; SIRT1 PROTEIN, HUMAN;

ABDOMINAL OBESITY; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC MUSCLE CELL; CARDIOVASCULAR MAGNETIC RESONANCE; CONTROLLED STUDY; DB/DB MOUSE; DOWN REGULATION; EPICARDIAL FAT; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INTRAPERITONEAL FAT; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WAIST CIRCUMFERENCE; AGED; ANIMAL; CHEMISTRY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FLOW CYTOMETRY; GENETICS; METABOLISM; MIDDLE AGED; MOUSE MUTANT; OBESITY; OBESITY, ABDOMINAL; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADIPOSITY; ADULT; AGED; ANIMALS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FLOW CYTOMETRY; HUMANS; MALE; MICE; MICE, OBESE; MICRORNAS; MIDDLE AGED; OBESITY, ABDOMINAL; PHOSPHODIESTERASE 5 INHIBITORS; REAL-TIME POLYMERASE CHAIN REACTION; SILDENAFIL CITRATE; SIRTUIN 1;

EID: 84984690362     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-4252     Document Type: Article

References (41)

1. Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007;116:39-48.
2. Kremen J, Dolinkova M, Krajickova J, et al. Increased subcutaneous and epicardial adipose tissue production of proinflammatory cytokines in cardiac surgery patients: possible role in postoperative insulin resistance. J Clin Endocrinol Metab. 2006;91:4620-4627.
3. Bettencourt N, Toschke AM, Leite D, et al. Epicardial adipose tissue is an independent predictor of coronary atherosclerotic burden. Int J Cardiol. 2012;158:26-32.
4. Mahabadi AA, Lehmann N, Kälsch H, et al. Association of epicardial adipose tissue with progression of coronary artery calcification is more pronounced in the early phase of atherosclerosis: results from the Heinz Nixdorf recall study. JACC Cardiovasc Imaging. 2014;7:909-916.
5. Iacobellis G, Leonetti F. Epicardial adipose tissue and insulin resistance in obese subjects. J Clin Endocrinol Metab. 2005;90:6300-6302.
6. Kim HM, Kim KJ, Lee HJ, et al. Epicardial adipose tissue thickness is an indicator for coronary artery stenosis in asymptomatic type 2 diabetic patients: its assessment by cardiac magnetic resonance. Cardiovasc Diabetol. 2012;11:83.
7. Giannetta E, Isidori AM, Galea N, et al. Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circulation. 2012;125:2323-2333.
8. Giannetta E, Feola T, Gianfrilli D, et al. Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe?Ameta-analysis of randomized controlled trials. BMC Med. 2014;12:185.
9. Santi D, Giannetta E, Isidori AM, Vitale C, Aversa A, Simoni M. Therapy of endocrine disease. Effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: a meta-analysis. Eur J Endocrinol. 2015;172:R103-R114.
10. Mandosi E, Giannetta E, Filardi T, et al. Endothelial dysfunction markers as a therapeutic target for Sildenafil treatment and effects on metabolic control in type 2 diabetes. Expert Opin Ther Targets. 2015;19(12):1617-1622.
11. Venneri MA, Giannetta E, Panio G, et al. Chronic inhibition of PDE5 limits pro-inflammatory monocyte-macrophage polarization in streptozotocin-induced diabetic mice. PLoS One. 2015;10: e0126580.
12. Ramirez CE, Nian H, Yu C, et al. Treatment with Sildenafil improves insulin sensitivity in prediabetes: a randomized, controlled trial. J Clin Endocrinol Metab. 2015;100:4533-4540.
13. Zhang X, Ji J, Yan G, et al. Sildenafil promotes adipogenesis through a PKG pathway. Biochem Biophys Res Commun. 2010;396:1054-1059.
14. Handa P, Tateya S, Rizzo NO, et al. Reduced vascular nitric oxidecGMP signaling contributes to adipose tissue inflammation during high-fat feeding. Arterioscler Thromb Vasc Biol. 2011;31:2827-2835.
15. Mitschke MM, Hoffmann LS, Gnad T, et al. Increased cGMP promotes healthy expansion and browning of white adipose tissue. FASEB J. 2013;27:1621-1630.
16. Ayala JE, Bracy DP, Julien BM, Rottman JN, Fueger PT, Wasserman DH. Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. Diabetes. 2007; 56:1025-1033.
17. Moore DR. Reverse translation: clearing a path from bedside to bench. Nature. 2008;454:274-274.
18. Mariani S, Fiore D, Basciani S, et al. Plasma levels of SIRT1 associate with non-alcoholic fatty liver disease in obese patients. Endocrine. 2015;49:711-716.
19. Nelson AJ, Worthley SG, Cameron JD, et al. Cardiovascular magnetic resonance-derived aortic distensibility: validation and observed regional differences in the elderly. J Hypertens. 2009;27:535-542.
20. Joe AW, Yi L, Even Y, Vogl AW, Rossi FM. Depot-specific differences in adipogenic progenitor abundance and proliferative response to high-fat diet. Stem Cells. 2009;27:2563-2570.
21. Lemos DR, Babaeijandaghi F, Low M, et al. Nilotinib reduces muscle fibrosis in chronic muscle injury by promoting TNF-mediated apoptosis of fibro/adipogenic progenitors. Nat Med. 2015;21:786-794.
22. Huang ZP, Chen J, Seok HY, et al. MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress. Circ Res. 2013; 112:1234-1243.
23. Humphreys DT, Hynes CJ, Patel HR, et al. Complexity of murine cardiomyocyte miRNA biogenesis, sequence variant expression and function. PLoS One. 2012;7:e30933.
24. Maneschi E, Cellai I, Aversa A, et al. Tadalafil reduces visceral adipose tissue accumulation by promoting preadipocytes differentiation towards a metabolically healthy phenotype: studies in rabbits. Mol Cell Endocrinol. 2016:424:50-70.
25. Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr. 2004;79:379-384.
26. Mazurek T, Zhang L, Zalewski A, et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation. 2003; 108:2460-2466.
27. Kim MK, Tomita T, Kim MJ, Sasai H, Maeda S, Tanaka K. Aerobic exercise training reduces epicardial fat in obese men. J Appl Physiol. 2009;106:5-11.
28. Xu XD, Song XW, Li Q, Wang GK, Jing Q, Qin YW. Attenuation of microRNA-22 derepressed PTEN to effectively protect rat cardiomyocytes from hypertrophy. J Cell Physiol. 2012;227:1391-1398.
29. Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail. 2011;4:8-17.
30. Gurha P, Wang T, Larimore AH, et al. microRNA-22 promotes heart failure through coordinate suppression of PPAR/ERR-nuclear hormone receptor transcription. PLoS One. 2013;8:e75882.
31. Picard F, Kurtev M, Chung N, et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-γ. Nature. 2004;429:771-776.
32. Feige JN, Lagouge M, Canto C, et al. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab. 2008;8: 347-358.
33. Qiao L, Shao J. SIRT1 regulates adiponectin gene expression through Foxo1-C/enhancer-binding protein α transcriptional complex. J Biol Chem. 2006;281:39915-39924.
34. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444:337-342.
35. Song YS, Lee SK, Jang YJ, et al. Association between low SIRT1 expression in visceral and subcutaneous adipose tissues and metabolic abnormalities in women with obesity and type 2 diabetes. Diabetes Res Clin Pract. 2013;101:341-348.
36. Gillum MP, Kotas ME, Erion DM, et al. SirT1 regulates adipose tissue inflammation. Diabetes. 2011;60:3235-3245.
37. Koka S, Aluri HS, Xi L, Lesnefsky EJ, Kukreja RC. Chronic inhibition of phosphodiesterase 5 with tadalafil attenuates mitochondrial dysfunction in type 2 diabetic hearts: potential role of NO/SIRT1/PGC-1α signaling. Am J Physiol Heart Circ Physiol. 2014; 306:H1558-H1568.
38. Shalwala M, Zhu SG, Das A, Salloum FN, Xi L, Kukreja RC. Sirtuin 1 (SIRT1) activation mediates sildenafil induced delayed cardioprotection against ischemia-reperfusion injury in mice. PLoS One. 2014;9:e86977.
39. Nisoli E, Tonello C, Cardile A, et al. Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science. 2005;310:314-317.
40. Xu F, Burk D, Gao Z, et al. Angiogenic deficiency and adipose tissue dysfunction are associated with macrophage malfunction in SIRT1-/- mice. Endocrinology. 2012;153:1706-1716.
41. Huang S, Wang S, Bian C, et al. Upregulation of miR-22 promotes osteogenic differentiation and inhibits adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells by repressing HDAC6 protein expression. Stem Cells Dev. 2012;21:2531-2540.